These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

862 related articles for article (PubMed ID: 17163259)

  • 21. Phase I study of weekly alternating therapy with irinotecan/cisplatin and etoposide/cisplatin for patients with small-cell lung cancer.
    Johnson FM; Kurie JM; Peeples BO; Lee JJ; Feng L; Pisters KM; Fossella FV; Papadimitrakopoulou VA; Blumenschein GR; Komaki R; Glisson BS
    Clin Lung Cancer; 2003 Jul; 5(1):40-5. PubMed ID: 14596703
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase I study of topotecan/paclitaxel alternating with etoposide/cisplatin and thoracic irradiation in patients with limited small cell lung cancer.
    Lu C; Komaki R; Lee JS; Shin DM; Palmer JL; Coldman BJ; Pisters KM; Kurie JM; Fossella FV; Glisson BS
    Clin Cancer Res; 2003 Jun; 9(6):2085-91. PubMed ID: 12796372
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Carboplatin + epirubicin +VP-16 + lenograstim followed by radiotherapy + carboplatin as radiosensitizer in limited small cell lung cancer. A multicenter phase II study.
    Gridelli C; Curcio C; Iaffaioli RV; Brancaccio L; D'Aprile M; Gebbia V; Rossi A; Tortoriello A; Veltri E; Maione P; Barbarisi A; Gallo C; Guida C; Perrone F
    Anticancer Res; 2001; 21(6A):4179-83. PubMed ID: 11911315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Topotecan-carboplatin-etoposide combination as 1st line treatment in patients with small cell lung cancer.
    Zarogoulidis K; Mylonaki E; Kakavelas P; Zarogoulidis P; Tsiouda T; Rapti E; Lithoxopoulou H; Zarogoulidou V; Kontakiotis T;
    Lung Cancer; 2009 Nov; 66(2):226-30. PubMed ID: 19321222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I trial of etoposide, carboplatin, and GM-CSF in extensive small-cell lung cancer: a Cancer and Leukemia Group B study (CALGB 8832).
    Luikart SD; Herndon JE; Hollis DR; MacDonald M; Maurer LH; Crawford J; Clamon GH; Wright J; Perry MC; Ozer H; Green MR
    Am J Clin Oncol; 1997 Feb; 20(1):24-30. PubMed ID: 9020283
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small-cell lung cancer: E7593--a phase III trial of the Eastern Cooperative Oncology Group.
    Schiller JH; Adak S; Cella D; DeVore RF; Johnson DH
    J Clin Oncol; 2001 Apr; 19(8):2114-22. PubMed ID: 11304763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer.
    Mavroudis D; Papadakis E; Veslemes M; Tsiafaki X; Stavrakakis J; Kouroussis C; Kakolyris S; Bania E; Jordanoglou J; Agelidou M; Vlachonicolis J; Georgoulias V;
    Ann Oncol; 2001 Apr; 12(4):463-70. PubMed ID: 11398877
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities.
    Hainsworth JD; Gray JR; Stroup SL; Kalman LA; Patten JE; Hopkins LG; Thomas M; Greco FA
    J Clin Oncol; 1997 Dec; 15(12):3464-70. PubMed ID: 9396399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Standard- and high-dose etoposide, ifosfamide, carboplatin, and epirubicin in 100 patients with small-cell lung cancer: a mature follow-up report.
    Fetscher S; Brugger W; Engelhardt R; Kanz L; Hasse J; Frommhold H; Lange W; Mertelsmann R
    Ann Oncol; 1999 May; 10(5):561-7. PubMed ID: 10416006
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
    Glisson B; Lee JS; Palmer J; Fossella F; Shin DM; Murphy WK; Perez-Soler R; Hong WK
    Cancer; 1998 Jan; 82(2):301-8. PubMed ID: 9445186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase II study of irinotecan plus cisplatin induction followed by concurrent twice-daily thoracic irradiation with etoposide plus cisplatin chemotherapy for limited-disease small-cell lung cancer.
    Han JY; Cho KH; Lee DH; Kim HY; Kim EA; Lee SY; Lee JS
    J Clin Oncol; 2005 May; 23(15):3488-94. PubMed ID: 15908658
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Repetitive high-dose topotecan, carboplatin, and paclitaxel with peripheral blood progenitor cell support in previously untreated ovarian cancer: results of a Phase I study.
    Prince HM; Rischin D; Quinn M; Allen D; Planner R; Neesham D; Gates P; Davison J
    Gynecol Oncol; 2001 May; 81(2):216-24. PubMed ID: 11330952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
    Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T;
    Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase I study of topotecan plus carboplatin for relapsed SCLC: WJTOG trial.
    Kurata T; Kashii T; Takeda K; Seki N; Tsuboi M; Kobayashi M; Satoh T; Nakagawa K; Fukuoka M
    J Thorac Oncol; 2009 May; 4(5):644-8. PubMed ID: 19325498
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Carboplatin, etoposide, and ifosfamide as intensive chemotherapy for small-cell lung cancer.
    Smith IE; Perren TJ; Ashley SA; Woodiwiss J; Forgeson GV; Yarnold JR; Ford HT
    J Clin Oncol; 1990 May; 8(5):899-905. PubMed ID: 2159056
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Double-cycle, high-dose ifosfamide, carboplatin, and etoposide followed by peripheral blood stem-cell transplantation for small cell lung cancer.
    Iwasaki Y; Nagata K; Nakanishi M; Natuhara A; Kubota Y; Ueda M; Arimoto T; Hara H
    Chest; 2005 Oct; 128(4):2268-73. PubMed ID: 16236883
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial.
    Greco FA; Thompson DS; Morrissey LH; Erland JB; Burris HA; Spigel DR; Joseph G; Corso SW; Spremulli E; Hainsworth JD
    Oncologist; 2005 Oct; 10(9):728-33. PubMed ID: 16249353
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients.
    Steward WP; von Pawel J; Gatzemeier U; Woll P; Thatcher N; Koschel G; Clancy L; Verweij J; de Wit R; Pfeifer W; Fennelly J; von Eiff M; Frisch J
    J Clin Oncol; 1998 Feb; 16(2):642-50. PubMed ID: 9469353
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A phase I/II study of docetaxel, etoposide, and carboplatin before concurrent chemoradiotherapy with cisplatin and etoposide in limited-stage small cell lung cancer.
    Sunpaweravong P; Magree L; Rabinovitch R; Bunn P; Kelly K
    Invest New Drugs; 2006 May; 24(3):213-21. PubMed ID: 16193241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer.
    Ihde DC; Mulshine JL; Kramer BS; Steinberg SM; Linnoila RI; Gazdar AF; Edison M; Phelps RM; Lesar M; Phares JC
    J Clin Oncol; 1994 Oct; 12(10):2022-34. PubMed ID: 7931470
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.